Skip to Main Content

Paper Details

Efficacy and Safety of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Age: The DELIVER Trial.
Circ Heart Fail
29
2022
Dapagliflozin, Heart Failure, Patients, cardiovascular death, dapagliflozin, heart failure, patients
Author NameAffiliation
Akshay S DesaiBrigham and Women's Hospital, Harvard Medical School
Rudolf A de BoerUniversity of Groningen, University Medical Center Groningen
David L DeMetsUniversity of Wisconsin
David L DeMetsUniversity of Wisconsin
Adrian F HernandezDuke University Medical Center
Mikhail KosiborodSaint Luke's Mid America Heart Institute and University of Missouri-Kansas City (M.N.K.).
Carolyn S P LamNational Heart Centre Singapore and Duke-National University of Singapore (C.S.P.L.).
  • 1 - 7

Datasets